London, ON – TheNewswire - March 23 2021 – TroyMedia Corp. is Canada’s latest Media leader to be drawn to Sernova Corp.’s (TSXV:SVA) (OTC:SEOVF) story and developments.

TroyMedia was founded in 2005 and since then has become the largest independent provider of original feature and analysis in Canada. Content distributed by TroyMedia appears in Canadian newspapers and news sites daily.

Its content is also received by more than 1,300 working journalists, who either republish it or use it as a basis for their own research. Newspapers that have carried its content include The Globe and Mail, National Post, and all the major Postmedia and Sun outlets.

Sernova’s news coverage was Business Front-Page Thursday March 18th in the following publications, with the headline:

“A Canadian Path to a Regenerative Cure to Type 1 Diabetes”

Troy Media
MicroNews.ca
Edmonton's Business
Camrose Voice
Kindersley Clarion
West-Central Crossroads
Strathmore Voice
Ingersoll Voice
Kirkland Lake Voice
Pembroke Voice
Kapuskasing Voice
Norwich Voice
Camrose Voice (see "Business")
Rosetown Eagle ("Business")
Portage Citizen ("Business")
Nelson Voice
Warman Voice
Rockyford Voice (Click "Business" upper left)
Fort MacKay Voice (Click "Business" upper left)
Hussar Voice
Bluenose Bulletin
Sask Valley Voice
Etobicoke Voice
Grande Cache Voice

Sernova followers and stakeholder are encouraged to share the following coverage via their own Social Media feeds.

Additional, new media interest is forthcoming and all interested parties are invited to Bookmark Sernova’s website or subscribe to the company’s Twitter, YouTube and LinkedIn channels.

About Sernova Corp.

Sernova is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells, and stem cell-derived cells) to improve the treatment and qu ality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com .

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dominic Gray

Sernova Corp

T: (519) 858-5126

dominic.gray@sernova.com

www.sernova.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Cautionary Statement Regarding Forward-Looking Information

This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Sernova’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the intended use of proceeds by the Company. Forward-looking information is based on reasonable assumptions that have been made by Sernova at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Examples of such risk factors include: credit; market (including equity, foreign exchange and interest rate); liquidity; operational (including technology and infrastructure); reputational; insurance; strategic; regulatory; legal; environmental; capital adequacy; the general business and economic conditions in the regions in which the Company operates; the ability of the Company to execute on key priorities, including the successful development of its product candidates, and strategic plans and to attract, develop and retain key executives; the ability to implement business strategies and pursue business opportunities; disruptions in or attacks (including cyber-attacks) on the Company's information technology; the failure of third parties to comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application of, current laws and regulations governing the Company’s business; dependence on key suppliers; granting of permits and licenses; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the occurrence of natural and unnatural catastrophic events and claims resulting from such events; risks related to COVID-19 including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, nonessential business closures, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, economic activity, financing, supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession; as well as those risk factors disclosed under the heading “Risk Factors” in the Company’s Annual Information Form (dated February 8, 2021) for the year ended October 31, 2020, which has been filed on SEDAR and is available under the Company’s profile at www.sedar.com. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Sernova is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein.